Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4606 to 4620 of 8974 results

  1. Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps, leaflets and messaging) help dental teams to provide people with support to improve their oral health?

    Recommendation ID NG30/3 Question Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps

  2. Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

    Recommendation ID IPG669/1 Question Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

  3. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    Recommendation ID CG148/4 Question Bladder management strategies:- What are the long-term risks and effects on quality of life of different

  4. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    Recommendation ID CG146/4 Question Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of

  5. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    Recommendation ID NG132/1 Question What is the clinical utility of bone turnover markers in the diagnosis and management of primary...

  6. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    Recommendation ID CG145/3 Question Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when

  7. Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for clinical trials of management of Lyme disease?

    Recommendation ID NG95/1 Question Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for

  8. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    Recommendation ID NG14/02 Question Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment

  9. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    Recommendation ID NG14/01 Question Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response

  10. Detection and management of respiratory disorders in primary and community care:- Can detection and management of respiratory disorders in adults with cerebral palsy be improved in primary and community care?

    Recommendation ID NG119/3 Question Detection and management of respiratory disorders in primary and community care:- Can detection and

  11. Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum antibiotic therapy, without adversely affecting outcomes?

    Recommendation ID CG191/4 Question Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum

  12. Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?

    Recommendation ID NG196/7 Question Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people

  13. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory